Ataxin-3L [6His-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Name: Machado-Joseph disease protein 1-like

Cat. No. Lot. No.	64-0034-050 30077	

Deconjugating enzymes (DCEs) are

proteases that process ubiquitin or

ubiquitin-like gene products, reverse

the modification of proteins by a single

ubiquitin or ubiquitin-like protein (UBL)

and remodel polyubiquitin (or poly-UBL)

chains on target proteins (Reyes-Turcu

et al., 2009). The deubiquitylating - or

deubiquitinating - enzymes (DUBs)

represent the largest family of DCEs

and regulate ubiquitin dependent sig-

nalling pathways. The activities of the

DUBs include the generation of free

ubiquitin from precursor molecules,

the recycling of ubiquitin following sub-

strate degradation to maintain cellular

ubiquitin homeostasis and the removal of ubiquitin or ubiquitin-like proteins (UBL) modifications through chain edit-

ing to rescue proteins from proteasomal degradation or to influence cell signal-

ling events (Komander et al., 2009).

There are two main classes of DUB;

cysteine proteases and metallopro-

teases. Ataxin-3L is a cysteine protease

and a member of the Machado-Joseph

Domain (MJD) enzyme family. Cloning

of the human gene was first described

by Gerhard et al. (2004). Machado-Jo-

seph disease (MJD), the most common

form of spinocerebellar ataxia world-

wide, is a progressive and ultimately fatal neurodegenerative disorder caused

by polyQ expansion in ataxin-3, a conserved and ubiguitous protein known to

bind polyubiquitin chains and to function as a deubiquitylating enzyme. Ataxin-3

has been linked to protein homeostasis

Quantity: 50 µg Storage: -70°C

NOT FOR USE IN HUMANS

FOR RESEARCH USE ONLY

Background

Physical Characteristics

Species: human

Source: E. coli

Quantity: 50 µg


Concentration: 0.5 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~43 kDa

Purity: >92% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required




 $\label{eq:mgsshhhhhhssglevergeggsmdfif \\ Hekqegflcaqhclnnllqgeyfspvela \\ Siahqldeeermrmaeggvtseeylaflqqpsen \\ Mddtgffsiqvisnalkfwgleiihfnnpey \\ Qklgidpinersficnykqhwftirkfgkhwfn \\ lnsllagpelisdtclanflarlqqqaysvfv \\ Vkgdlpdceadqllqiisveemdtpklngk \\ klvkqkehrvyktvlekvseesdesgtsdqdeed \\ fqralelsrqetnredehlrstielsmqgss \\ gntsqdlpktscvtpaseqpkkikedy \\ Fekhqqeqkqqqqqsdlpghssylherpttss \\ raiesdlsddisegtvqaavdtileimrknlkik \\ gek \\ \end{aligned}$

Tag (**bold text**): N-terminal His Protease cleavage site: PreScission [™] (<u>LEVLFQ▼GP</u>) Ataxin-3L (regular text): Start **bold italics** (amino acid residues 1-355) Accession number: NP_001129467

Quality Assurance

Purity:

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 μg His-Ataxin-3L



Protein Identification:

Confirmed by mass spectrometry.

Deubiquitylase Enzyme Assay:

The activity of His-Ataxin-3L was validated by determining the increase in fluorescence measured as a result of the enzyme catalysed cleavage of the fluorogenic substrate Ubiquitin-Rhodamine110-Glycine generating Ubiquitin and Rhodamine110-Glycine. Incubation of the substrate in the presence or absence of His-Ataxin-3L was compared confirming the deubiquitylating activity of His-Ataxin-3L.



Continued on page 2

ORDERS / SALES SUPPORT International: +1-617-245-0003 US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0



CERTIFICATE OF ANALYSIS Page 1 of 2

Ataxin-3L [6His-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Name: Machado-Joseph disease protein 1-like

30077

64-0034-050



FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

Quantity:

Storage:

CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Cat. No.

Lot. No.

Continued from page 1

maintenance, transcription, cytoskeleton regulation and myogenesis (Matos *et al.*, 2011). Ataxin-3L shares 85% sequence identity with ataxin-3 although it has recently been shown that the Josephin domain of ataxin-3L demonstrates substantially higher deubiquitylating activity than the ataxin-3 Josephin domain (Weeks *et al.*, 2011).

References:

Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, *et al.* (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). *Genome Res* **14**, 2121-2127.

Komander D, Clague MJ, Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* **10**, 550-563.

Matos CA, de Macedo-Ribeiro S, Carvalho AL (2011) Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. *Prog Neurobiol* **95**, 26-48.

Reyes-Turcu FE, Ventii KH, Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. *Ann Rev Biol* **78**, 363-397.

Weeks SD, Grasty KC, Hernandez-Cuebas L, Loll PJ (2011) Crystal structure of a Josephin-ubiquitin complex: evolutionary restraints on ataxin-3 deubiquitinating activity. *J Biol Chem* **286**, 4555-4565.



ORDERS / SALES SUPPORT

 International:
 +1-617-245-0003

 US Toll-Free:
 1-888-4E1E2E3 (1-888-431-3233)

 Email:
 sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative QR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0